Welcome to our dedicated page for Haemonetics Mass SEC filings (Ticker: HAE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haemonetics Corporation (NYSE: HAE) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Massachusetts corporation and NYSE-listed issuer, Haemonetics reports material events, financial results and shareholder matters through forms such as Form 8-K.
Recent 8-K filings show several key categories of information. Under Item 2.02, Haemonetics furnishes press releases announcing quarterly financial results, including results for specific fiscal quarters and the first half of a fiscal year. These filings clarify that the furnished earnings releases are not deemed filed for purposes of Section 18 of the Exchange Act but provide investors with detailed financial updates.
Another important filing type is the Item 8.01 Other Events 8-K, such as the report dated January 9, 2026 describing Haemonetics’ acquisition of Vivasure Medical Limited. That filing outlines the terms of the transaction, including upfront consideration, contingent payments based on sales growth and milestone achievements, and the use of available cash on hand to finance the acquisition. It also references the related press release furnished as an exhibit.
Haemonetics’ SEC filings also document shareholder meeting results. An 8-K under Item 5.07 details the outcomes of votes at the 2025 Annual Meeting of Shareholders, including the election of directors, advisory approval of executive compensation and ratification of the independent registered public accounting firm.
On Stock Titan, these filings are updated as they appear on EDGAR, and AI-powered tools can help summarize long documents, highlight key sections and surface items such as earnings disclosures, acquisition terms and shareholder vote results. This allows users to review Haemonetics’ regulatory history, understand significant corporate events and see how the company communicates financial and governance information to the market.
Haemonetics Corporation Form 144 Notice details a proposed sale of 18,630 shares of common stock with an aggregate market value of $1,396,132.20 through Fidelity Brokerage Services on the NYSE, planned for June 26, 2025.
The shares were acquired through multiple restricted stock vestings between 2020-2025:
- 2020-2022: 469 shares total from two vestings
- 2023: 4,455 shares from three vestings
- 2025: 13,706 shares from four recent vestings
The filing also discloses a previous sale by Josep L. Llorens of 1,547 shares on May 19, 2025, generating proceeds of $107,319.26. All shares were acquired as compensation through restricted stock vestings, representing approximately 0.04% of the total 48,036,996 shares outstanding.